Oncolytic reactivation of KSHV as a therapeutic approach for primary effusion lymphoma

Feng Zhou, Michiko Shimoda, Laura Olney, Yuanzhi Lyu, Khiem Tran, Guochun Jiang, Kazushi Nakano, Ryan R. Davis, Clifford G Tepper, Emanual Maverakis, Mel Campbell, Yuanpei Li, Satya Dandekar, Yoshihiro Izumiya

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Primary effusion lymphoma (PEL) is an aggressive subtype of non-Hodgkin lymphoma caused by Kaposi's sarcoma-associated herpesvirus (KSHV) infection. Currently, treatment options for patients with PEL are limited. Oncolytic viruses have been engineered as anticancer agents and have recently shown increased therapeutic promise. Similarly, lytic activation of endogenous viruses from latently infected tumor cells can also be applied as a cancer therapy. In theory, such a therapeutic strategy would induce oncolysis by viral replication, while simultaneously stimulating an immune response to viral lytic cycle antigens. We examined the combination of the FDA-approved drug ingenol-3-angelate (PEP005) with epigenetic drugs as a rational therapeutic approach for KSHV-mediated malignancies. JQ1, a bromodomain and extra terminal (BET) protein inhibitor, in combination with PEP005, not only robustly induced KSHV lytic replication, but also inhibited IL6 production from PEL cells. Using the dosages of these agents that were found to be effective in reactivating HIV (as a means to clear latent virus with highly active antiretroviral therapy), we were able to inhibit PEL growth in vitro and delay tumor growth in a PEL xenograft tumor model. KSHV reactivation was mediated by activation of the NF-kB pathway by PEP005, which led to increased occupancy of RNA polymerase II onto the KSHV genome. RNA-sequencing analysis further revealed cellular targets of PEP005, JQ1, and the synergistic effects of both. Thus, combination of PEP005 with a BET inhibitor may be considered as a rational therapeutic approach for the treatment of PEL.

Original languageEnglish (US)
Pages (from-to)2627-2638
Number of pages12
JournalMolecular Cancer Therapeutics
Volume16
Issue number11
DOIs
StatePublished - Nov 1 2017

Fingerprint

Primary Effusion Lymphoma
Human Herpesvirus 8
Neoplasms
Therapeutics
Oncolytic Viruses
RNA Sequence Analysis
Virus Activation
Herpesviridae Infections
RNA Polymerase II
NF-kappa B
Highly Active Antiretroviral Therapy
Growth
Heterografts
Epigenomics
Pharmaceutical Preparations
Antineoplastic Agents
Non-Hodgkin's Lymphoma
3-ingenyl angelate
Interleukin-6
HIV

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Oncolytic reactivation of KSHV as a therapeutic approach for primary effusion lymphoma. / Zhou, Feng; Shimoda, Michiko; Olney, Laura; Lyu, Yuanzhi; Tran, Khiem; Jiang, Guochun; Nakano, Kazushi; Davis, Ryan R.; Tepper, Clifford G; Maverakis, Emanual; Campbell, Mel; Li, Yuanpei; Dandekar, Satya; Izumiya, Yoshihiro.

In: Molecular Cancer Therapeutics, Vol. 16, No. 11, 01.11.2017, p. 2627-2638.

Research output: Contribution to journalArticle

Zhou, Feng ; Shimoda, Michiko ; Olney, Laura ; Lyu, Yuanzhi ; Tran, Khiem ; Jiang, Guochun ; Nakano, Kazushi ; Davis, Ryan R. ; Tepper, Clifford G ; Maverakis, Emanual ; Campbell, Mel ; Li, Yuanpei ; Dandekar, Satya ; Izumiya, Yoshihiro. / Oncolytic reactivation of KSHV as a therapeutic approach for primary effusion lymphoma. In: Molecular Cancer Therapeutics. 2017 ; Vol. 16, No. 11. pp. 2627-2638.
@article{b32caa1f46e54d47a55639f7d2173bac,
title = "Oncolytic reactivation of KSHV as a therapeutic approach for primary effusion lymphoma",
abstract = "Primary effusion lymphoma (PEL) is an aggressive subtype of non-Hodgkin lymphoma caused by Kaposi's sarcoma-associated herpesvirus (KSHV) infection. Currently, treatment options for patients with PEL are limited. Oncolytic viruses have been engineered as anticancer agents and have recently shown increased therapeutic promise. Similarly, lytic activation of endogenous viruses from latently infected tumor cells can also be applied as a cancer therapy. In theory, such a therapeutic strategy would induce oncolysis by viral replication, while simultaneously stimulating an immune response to viral lytic cycle antigens. We examined the combination of the FDA-approved drug ingenol-3-angelate (PEP005) with epigenetic drugs as a rational therapeutic approach for KSHV-mediated malignancies. JQ1, a bromodomain and extra terminal (BET) protein inhibitor, in combination with PEP005, not only robustly induced KSHV lytic replication, but also inhibited IL6 production from PEL cells. Using the dosages of these agents that were found to be effective in reactivating HIV (as a means to clear latent virus with highly active antiretroviral therapy), we were able to inhibit PEL growth in vitro and delay tumor growth in a PEL xenograft tumor model. KSHV reactivation was mediated by activation of the NF-kB pathway by PEP005, which led to increased occupancy of RNA polymerase II onto the KSHV genome. RNA-sequencing analysis further revealed cellular targets of PEP005, JQ1, and the synergistic effects of both. Thus, combination of PEP005 with a BET inhibitor may be considered as a rational therapeutic approach for the treatment of PEL.",
author = "Feng Zhou and Michiko Shimoda and Laura Olney and Yuanzhi Lyu and Khiem Tran and Guochun Jiang and Kazushi Nakano and Davis, {Ryan R.} and Tepper, {Clifford G} and Emanual Maverakis and Mel Campbell and Yuanpei Li and Satya Dandekar and Yoshihiro Izumiya",
year = "2017",
month = "11",
day = "1",
doi = "10.1158/1535-7163.MCT-17-0041",
language = "English (US)",
volume = "16",
pages = "2627--2638",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Oncolytic reactivation of KSHV as a therapeutic approach for primary effusion lymphoma

AU - Zhou, Feng

AU - Shimoda, Michiko

AU - Olney, Laura

AU - Lyu, Yuanzhi

AU - Tran, Khiem

AU - Jiang, Guochun

AU - Nakano, Kazushi

AU - Davis, Ryan R.

AU - Tepper, Clifford G

AU - Maverakis, Emanual

AU - Campbell, Mel

AU - Li, Yuanpei

AU - Dandekar, Satya

AU - Izumiya, Yoshihiro

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Primary effusion lymphoma (PEL) is an aggressive subtype of non-Hodgkin lymphoma caused by Kaposi's sarcoma-associated herpesvirus (KSHV) infection. Currently, treatment options for patients with PEL are limited. Oncolytic viruses have been engineered as anticancer agents and have recently shown increased therapeutic promise. Similarly, lytic activation of endogenous viruses from latently infected tumor cells can also be applied as a cancer therapy. In theory, such a therapeutic strategy would induce oncolysis by viral replication, while simultaneously stimulating an immune response to viral lytic cycle antigens. We examined the combination of the FDA-approved drug ingenol-3-angelate (PEP005) with epigenetic drugs as a rational therapeutic approach for KSHV-mediated malignancies. JQ1, a bromodomain and extra terminal (BET) protein inhibitor, in combination with PEP005, not only robustly induced KSHV lytic replication, but also inhibited IL6 production from PEL cells. Using the dosages of these agents that were found to be effective in reactivating HIV (as a means to clear latent virus with highly active antiretroviral therapy), we were able to inhibit PEL growth in vitro and delay tumor growth in a PEL xenograft tumor model. KSHV reactivation was mediated by activation of the NF-kB pathway by PEP005, which led to increased occupancy of RNA polymerase II onto the KSHV genome. RNA-sequencing analysis further revealed cellular targets of PEP005, JQ1, and the synergistic effects of both. Thus, combination of PEP005 with a BET inhibitor may be considered as a rational therapeutic approach for the treatment of PEL.

AB - Primary effusion lymphoma (PEL) is an aggressive subtype of non-Hodgkin lymphoma caused by Kaposi's sarcoma-associated herpesvirus (KSHV) infection. Currently, treatment options for patients with PEL are limited. Oncolytic viruses have been engineered as anticancer agents and have recently shown increased therapeutic promise. Similarly, lytic activation of endogenous viruses from latently infected tumor cells can also be applied as a cancer therapy. In theory, such a therapeutic strategy would induce oncolysis by viral replication, while simultaneously stimulating an immune response to viral lytic cycle antigens. We examined the combination of the FDA-approved drug ingenol-3-angelate (PEP005) with epigenetic drugs as a rational therapeutic approach for KSHV-mediated malignancies. JQ1, a bromodomain and extra terminal (BET) protein inhibitor, in combination with PEP005, not only robustly induced KSHV lytic replication, but also inhibited IL6 production from PEL cells. Using the dosages of these agents that were found to be effective in reactivating HIV (as a means to clear latent virus with highly active antiretroviral therapy), we were able to inhibit PEL growth in vitro and delay tumor growth in a PEL xenograft tumor model. KSHV reactivation was mediated by activation of the NF-kB pathway by PEP005, which led to increased occupancy of RNA polymerase II onto the KSHV genome. RNA-sequencing analysis further revealed cellular targets of PEP005, JQ1, and the synergistic effects of both. Thus, combination of PEP005 with a BET inhibitor may be considered as a rational therapeutic approach for the treatment of PEL.

UR - http://www.scopus.com/inward/record.url?scp=85032785372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032785372&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-17-0041

DO - 10.1158/1535-7163.MCT-17-0041

M3 - Article

C2 - 28847988

AN - SCOPUS:85032785372

VL - 16

SP - 2627

EP - 2638

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 11

ER -